Scholar Rock Holding Corporation (SRRK)
Scholar Rock: De-Risked Biotech, Playing The Approval Catalyst (Buy Rating)
Scholar Rock Holding Corporation (SRRK) is a clinical-stage biotech focused on targeted therapies for neuromuscular and fibrotic diseases, with Apitegromab as its lead asset. SRRK's Apitegromab achieved strong phase 3 results in spinal muscular atrophy, showing meaningful motor function gains and robust safety as an add-on therapy. The recent stock correction was due to manufacturing site issues, not clinical setbacks; approval is expected by 2026, presenting a speculative buy opportunity.
US FDA declines to approve Scholar Rock's muscle weakness drug
The U.S. Food and Drug Administration has declined to approve Scholar Rock's drug for a rare neuromuscular disease, citing issues at a third party manufacturing facility, the company said on Tuesday.
Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Akshay K. Vaishnaw - President of R&D, Member of Scientific Advisory Board and Director David L.
Scholar Rock Holding Corporation (SRRK) Q1 2025 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q1 2025 Earnings Conference Call May 14, 2025 8:15 AM ET Company Participants Rushmie Nofsinger - VP, Corporate Affairs and IR David Hallal - CEO Akshay Vaishnaw - President of R&D Keith Woods - COO Vikas Sinha - CFO Conference Call Participants Allison Bratzel - Piper Sandler Michael Yee - Jefferies Tessa Romero - JPMorgan David Nierengarten - Wedbush Gary Nachman - Raymond James Kripa Devarakonda - Truist Marc Frahm - TD Cowen Andres Maldonado - H.C. Wainwright Dennis Kennedy - LifeSci Capital Operator Ladies and gentlemen, thank you for standing by.
Why Scholar Rock Stock Took a Knock on Monday
Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. They get worried that significant changes could reflect instability, indecision, or both in a company's decision-making.
Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment
Scholar Rock Holding Corp. SRRK said on Sunday the company will present new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.
Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript
Scholar Rock Holding Corporation. (NASDAQ:SRRK ) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Tracey Sacco - Chief Commercial Officer Conference Call Participants Allison Bratzel - Piper Sandler Michael Yee - Jefferies Tessa Romero - JPMorgan Gary Nachman - Raymond James Operator Good morning and welcome to Scholar Rock's Fourth Quarter Financial Results and Business Update Call.
Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth
Scholar Rock Holding Corporation SRRK President & CEO Jay Backstrom presented at the J.P. Morgan Healthcare Conference.
Scholar Rock Holding Corporation (SRRK) Q3 2024 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q3 2024 Earnings Conference Call November 12, 2024 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Conference Call Participants Jenna Lee - Jefferies Etzer Darout - BMO Capital Markets Gary Nachman - Raymond James Alex Nugent - Truist Securities Limited Operator Good morning and welcome to Scholar Rock's Third Quarter 2024 Financial Results and Business Update Call. All participants will be in listen-only mode.
Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross?
Scholar Rock Holding Corporation (SRRK) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, SRRK's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Here's Why Everybody's Talking About Scholar Rock Right Now
Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers.
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal
Scholar Rock stock skyrockets as the late-stage study of the investigational therapy, apitegromab, to treat spinal muscular atrophy meets the primary goal.
